Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease.

ABSTRACT: Parkinson's disease (PD) is a devastating neurodegenerative disorder characterized by degeneration of the nigrostriatal dopaminergic pathway. Because the current therapies only lead to temporary, limited improvement and have severe side effects, new approaches to treat PD need to be developed. To discover new targets for potential therapeutic intervention, a chemical genetic approach involving the use of small molecules as pharmacological tools has been implemented. First, a screening of an in-house chemical library on a well-established cellular model of PD was done followed by a detailed pharmacological analysis of the hits. Here, we report the results found for the small heterocyclic derivative called SC001, which after different enzymatic assays was revealed to be a new glycogen syntha

SUBMITTER: Morales-Garcia JA 

PROVIDER: S-EPMC3582296 | biostudies-literature | 2013 Feb

REPOSITORIES: biostudies-literature